Timber Hill’s Alexion Pharmaceuticals ALXN Stock Holding History

Timber Hill’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-2,953	Closed	-$329K	–	293
2018 Q1	$329K	Buy	+2,953	New	+$353K	0.05%	216
2014 Q3	–	Sell	-3,116	Closed	-$512K	–	2900
2014 Q2	$487K	Buy	3,116 +1,085	+53%	+$171K	﹤0.01%	2121
2014 Q1	$309K	Sell	2,031 -13,213	-87%	-$2.1M	﹤0.01%	2347
2013 Q4	$2.03M	Sell	15,244 -17,597	-54%	-$2.11M	0.01%	1358
2013 Q3	$3.81M	Buy	32,841 +30,032	+1,069%	+$3.29M	0.01%	1025
2013 Q2	$259K	Buy	+2,809	New	+$271K	﹤0.01%	2878

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Timber Hill's ALXN Position: Q2 2018 in Review

Timber Hill sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 2,953 shares — an estimated $329K sold.

Timber Hill first reported a position in ALXN in Q2 2013 and held it in 6 quarters. The position peaked at $3.81M in Q3 2013. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

Timber Hill reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Timber Hill sold 2,953 Alexion Pharmaceuticals shares in Q2 2018, an estimated $329K.
Timber Hill first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
Timber Hill's Alexion Pharmaceuticals position peaked at $3.81M in Q3 2013.
601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Timber Hill's 13F filing for Q2 2018, filed 9 Aug 2018.